Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys

Experimental Neurology

Volumn 168, Issue 1, 2001, Pages 171-182

  Emborg, M E ^a   Shin, P ^a   Roitberg, B ^a,b   Sramek, J G ^a   Chu, Y ^a   Stebbins, G T ^a   Hamilton, J S ^c   Suzdak, P D ^c   Steiner, J P ^c   Kordower, J H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

Dopamine; Immunophilins; Monkeys; Neuroprotection; Parkinson's disease; Substantia nigra

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; IMMUNOPHILIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG SAFETY; MALE; NEUROPROTECTION; NONHUMAN; OPTICAL DENSITY; PARKINSON DISEASE; PRIORITY JOURNAL; RHESUS MONKEY; TASK PERFORMANCE;

EID: 0035123909     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7592     Document Type: Article

References (50)

1. The pole and collar system: A technique for handling and training non human primates
2. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
3. Intrastriatal injection of an adenoviral vector expressing glial cell line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease
4. Neuronal vulnerability and informatics in human disease
5. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
6. Dopaminergic neurons protected from degeneration by GDNF gene therapy
7. A consideration of neuronal counting methods
8. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
9. Variability and functional recovery in the N-methyl-4 phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys
10. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: Biochemical changes in striatal regions
11. Long-term MPTPtreated monkeys are resistant to GM1 systemic therapy
12. MPTP induced asymmetric parkinsonism in non human primates 6-8 years after a unilateral intracarotid (ica) dose
13. Age-related motor decline in rhesus monkeys: Stereological correlates of the nigrostriatal system
14. Functional recovery in GDNF-treated Parkinsonian monkeys
15. The immunosupressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury
16. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve
17. NGF and anti-transferrin receptor antibody conjugate: Short and long-term effects on survival of cholinergic neurons in intraocular septal transplants - NGF and anti-transferrin receptor antibody conjugate: Short and long-term effects on survival of cholinergic neurons in intraocular septal transplants
18. The novel small molecule immunophilin ligand GPI 1046 stimulates cholinergic reinervation of deafferented hippocampal regions after fimbria-fornix transection
19. The new stereological tools: Dissector, fractionator, nucleator, and point sampled intercepts and their use in pathological research in diagnosis
20. 6-[18F]Fluoro-L-m-tyrosine: Metabolism, PET kinetics, and MPTP lesions in primates
21. NGF-like trophic support from peripheral nerve for grafted rhesus adrenal chromaffin cells
22. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents degeneration of cholinergic striatal neurons in a model of Huntington's disease
23. Encapsulated PC12 cell transplants into hemiparkinsonian monkeys: A behavioral, neuroanatomical and neurochemical analysis
24. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease
25. Clinico-pathological findings following intraventricular GDNF treatment in a patient with Parkinson's disease
26. Oral levodopa dose-response study in MPTP induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism
27. The time course and magnitude of spontaneous recovery produced by intracarotid administration of 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine to monkeys
28. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
29. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the squirrel monkey
30. Glial cell line-derived neurotrophic factor: Distribution and pharmacology in the rat following a bolus intraventricular injection
31. Pharmacological characterization of glial cell line derived-neurotrophic factor: Implications for GDNF a therapeutic molecule to treat neurodegenerative diseases
32. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia
33. Neuronal regeneration enhances the expression of the immunophilin FKBP-12
34. Cell counts in the substantia nigra: A comparison of single section counts and dissector counts in patients with Parkinson's disease and in controls
35. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method
36. Striatal and non-striatal neurotransmitter changes in MPTP-parkinsonism in rhesus monkey: The symptomatic vs. the asymptomatic condition
37. Monoamino oxidase of the brains and livers of macaque and cercopithecus monkeys
38. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment
39. Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion
40. Chemistry and biology of he immunophilins and their immunosuppressive ligands
41. High brain densities of the immunophilin FKBP colocalized with calcineurin
42. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models
43. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A
44. GDNF redueces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine
45. GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system
46. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioral recovery from motor deficits induced by an earlier exposure to the neurotoxin
47. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset
48. Estimation of the number of somatostatin neurons in the striatum: An in situ hybridization study using the optical fractionator method
49. Peripheral cell types contributing to the hyperalgesic action of nerve growth factor in inflammation